PARP Inhibitors in the Management of Ovarian Cancer
Key Points
Key Points
- These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
- The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.
Treatment
...reatme...
...ating PARPi
Recommendation 1.0Repeating PARPi...
...ly Diagnosed Ovarian Cancer...
...commendation 2.0PARPi are NOT recommende...
...ate – Recommendation 2.1Patients wi...
...mmendation 2.2The addition of olaparib to bevaci...
...ecommendation 2.3Inclusion of the PAR...
...arian Cancer - Second-line or Greater Mainte...
...d Update – Recommendation...
...onotherapy maintenance (second-line o...
Maintenance treatment with niraparib for patient...
...date – Recommendation 3.1/3.2PARPi mono...
...d Update – Recommendation 3.3PARPi monothe...
...in Combination...
...ndation 4.0PARPi are NOT recommended for use...
...nt of Adverse Events...
...ndation 5.0 Anemia...
...s requiring a blood transfusion for symptom...
...tients with progressive anemia may be offered...
...ommendation 5.1 Neutrope...
...Growth factor is NOT indicated for use in...
.... Neutropenia (grade 4 lasting at least 5–7 da...
...ation 5.2 Platelets:...
...ytopenia is most common with niraparib. Nirapa...
...Discontinue PARPi for persistent t...
...on 5.3 Persistent cytopenia:Evaluation for...
...commendation 5.4 N...
a. Many patients will have tachyphy...
...t nausea requiring daily anti-emetic intervention,...
Table 1. PARP Inhibitors in the Manage...
...PARPi Use Opportunities in PARPi-Naïve W...